NASDAQ:QNCX 10 February 2026 - 11 February 2026

Quince Therapeutics shares jumped about 48% to 78 cents in premarket trading Wednesday after the company hired LifeSci Capital to explore strategic alternatives and liability restructuring. The move follows a failed late-stage drug trial and the resignation of five board directors. The stock surged from 13 cents Monday to 52.8 cents Tuesday on heavy volume. Investors await further disclosures or a timeline for next steps.

Quince Therapeutics shares dropped 6.6% to $0.13 in premarket trading after the company hired LifeSci Capital to advise on strategic alternatives and liability restructuring. The move follows a failed Phase 3 trial in late January and the resignation of five directors. Quince said it will not provide further updates unless its board approves a specific action.